{"id":"W4403665847","doi":"10.1200/jco.24.00529","title":"Trastuzumab Duocarmazine in Pretreated Human Epidermal Growth Factor Receptor 2–Positive Advanced or Metastatic Breast Cancer: An Open-Label, Randomized, Phase III Trial (TULIP)","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ottawa Hospital","funders":"Medac","keywords":"Medicine; Metastatic breast cancer; Trastuzumab; Internal medicine; Trastuzumab emtansine; Oncology; Hazard ratio; Breast cancer; Clinical endpoint; Pertuzumab; Lapatinib; Cancer; Progression-free survival; Clinical trial; Surgery; Chemotherapy; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001679047,0.001426398,0.001999342,0.0003941311,0.0003246131,0.0008963469,0.0006516569,0.0009777988,0.002688205],"category_scores_gemma":[0.00106082,0.0004187083,0.000914479,0.0003361842,0.0009823233,0.000842982,0.0004039707,0.001796253,0.0004446393],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007084737,"about_ca_system_score_gemma":0.001156819,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006817238,"about_ca_topic_score_gemma":0.001632487,"domain_scores_codex":[0.9995678,0.0002368504,0.00002115178,0.00007181772,0.00002710459,0.00007523705],"domain_scores_gemma":[0.9995602,0.0001105359,0.00008098482,0.00002575528,0.0000231355,0.0001994328],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9628787,0.01097046,0.0009412209,0.0003475246,0.0002918306,0.00004978071,0.0000828895,0.0004411401,0.00411708,0.0001314498,0.0006491083,0.01909889],"study_design_scores_gemma":[0.8958091,0.1009294,0.001381328,0.00002299246,0.0001998992,0.00003823339,0.0000214281,0.0005736508,0.0004757006,0.0001003327,0.0004378305,0.00001006758],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9938827,0.001845535,0.0003145065,0.0002347644,0.0001399459,0.002262769,0.0003610222,0.00005541562,0.0009034003],"genre_scores_gemma":[0.9909858,0.002084976,0.001016157,0.0004854121,0.0002484665,0.002923111,0.0007701521,0.00001410007,0.001471956],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002688205,"threshold_uncertainty_score":0.00899291,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2651344660519626,"score_gpt":0.5945402876781979,"score_spread":0.3294058216262353,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}